RM 048
Alternative Names: RM-048Latest Information Update: 06 Mar 2024
At a glance
- Originator REVOLUTION Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Oct 2023 Preclinical trials in Cancer in USA (unspecified route) prior to October 2023
- 11 Oct 2023 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical trial in cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)